摘要
目的分析慢性淋巴细胞白血病患者实施伊布替尼治疗的有效性和安全性。方法72例慢性淋巴细胞白血病患者,按照随机数字表法分为研究组与对照组,每组36例。研究组采用伊布替尼靶向治疗,对照组采用氟达拉滨+环磷酰胺化疗治疗。对比两组患者治疗前后体能状态评分、临床毒副反应发生情况及治疗效果。结果治疗前,两组体能状态评分对比,差异无统计学意义(P>0.05);治疗后,研究组体能状态评分(2.55±1.24)分低于对照组的(3.25±1.33)分,差异有统计学意义(P<0.05)。研究组治疗总有效率为97.22%,高于对照组的80.56%,差异有统计学意义(P<0.05)。研究组临床毒副反应发生率为19.44%,低于对照组的44.44%,差异有统计学意义(P<0.05)。结论伊布替尼靶向治疗慢性淋巴细胞白血病患者,可提升疾病治疗效果,对缩短疾病恢复进程具有积极意义,还可有效抑制临床毒副反应,安全性、可行性均较高,实现最佳预后,值得临床推广。
Objective To analyze the effectiveness and safety of ibrutinib in the treatment of chronic lymphocytic leukemia.Methods A total of 72 patients with chronic lymphocytic leukemia were divided into study group and control group according to random numerical table,with 36 cases in each group.The study group was treated with ibrutinib targeted therapy,while the control group was treated with fludarabine+cyclophosphamide chemotherapy.The performance status score before and after treatment,clinical toxicity,and therapeutic effect of the two groups were compared.Results Before treatment,there was no statistically significant difference in performance status score between the two groups(P>0.05).After treatment,the performance status score of(2.55±1.24)points in the study group was lower than that of(3.25±1.33)points in the control group,and the difference was statistically significant(P<0.05).The total effective rate of the study group was 97.22%,which was higher than that of 80.56%of the control group,and the difference was statistically significant(P<0.05).The incidence of clinical toxicity in the study group was 19.44%,which was lower than that of 44.44%in the control group,and the difference was statistically significant(P<0.05).Conclusion Ibrutinib targeted therapy in patients with chronic lymphocytic leukemia can improve the therapeutic effect of the disease.It has positive significance in shortening the disease recovery process,and can effectively inhibit clinical toxic reactions,with high safety and feasibility,and achieve the best prognosis,which is worthy of clinical promotion.
作者
王玉茹
WANG Yu-ru(Department of Hematology,The 989th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China,Luoyang 471000,China)
出处
《中国实用医药》
2023年第20期108-111,共4页
China Practical Medicine
